Art. 11 Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 Decembe…

In forcecited 2×
1.

Production of the information referred to in point (a) of Article 7(1) shall be waived for specific medicinal products or for classes of medicinal products, if there is evidence showing any of the following:

(a)

that the specific medicinal product or class of medicinal products is likely to be ineffective or unsafe in part or all of the paediatric population;

(b)

that the disease or condition for which the specific medicinal product or class is intended occurs only in adult populations;

(c)

that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

2.

The waiver provided for in paragraph 1 may be issued with reference either to one or more specified subsets of the paediatric population, or to one or more specified therapeutic indications, or to a combination of both.

  • Order of the President of the Court of First Instance of 24 April 2009. Nycomed Danmark ApS v Agence européenne des médicaments (EMEA).Decision

    24 Apr 2009 · 62009TO0052

  • Judgment of the General Court (Third Chamber) of 14 December 2011. Nycomed Danmark ApS v European Medicines Agency (EMA).Decision

    As was noted in paragraph 98 above, both the actions of the Paediatric Committee, which are confined to drawing up opinions after establishing the facts on the basis of scientifically-reasoned, objective evidence, and the decisions taken …

    14 Dec 2011 · 62009TJ0052